The Efficacy of Endoscopic Papillary Balloon Dilation for Patients with Acute Biliary Pancreatitis

Table 2

Results of EPBD and clinical parameters in overall patients and comparisons between mild (A) and severe (B) degree of acute biliary pancreatitis.

Results of EPBD	Overall ()	Group A ()	Group B ()	value
Time from admission to initial ERCP (days)	3.3 ± 2.4	3.4 ± 2.5	2.8 ± 1.5	0.08
Juxtapapillary diverticulum	55 (30.1%)	49 (31.6%)	6 (21.4%)	0.28
Dilated CBD	159 (86.9%)	136 (87.7%)	23 (82.1%)	0.42
Mean size of CBD (mm)	11.8 ± 4.2	11.9 ± 4.0	11.5 ± 5.0	0.75
Positive filling defects within CBD	149 (81.4%)	130 (83.9%)	19 (67.9%)	0.23
Mean size of CBD filling defects (mm)	6.8 ± 4.6	6.9 ± 4.7	6.0 ± 3.3	0.14
Dilating balloon size (mm)	10.5 ± 1.8	10.6 ± 1.9	9.9 ± 1.3	0.04
Dilating procedure duration (min)	4.3 ± 1.1	4.3 ± 1.1	4.3 ± 1.0	0.95
Gross stone retrieved from CBD	124 (67.8%)	108 (69.7%)	16 (57.1%)	0.19
Pancreatic duct injection	93 (50.8%)	74 (47.7%)	19 (67.9%)	0.05
Number of mechanical lithotripsies	2 (1.1%)	2 (1.3%)	0 (0.0%)	0.72
Treatment success
First session	179 (97.8%)	151 (97.4%)	28 (100%)	0.51
Second session	4	4	0
Procedure-related adverse events	4 (2.2%)	3 (1.9%)	1 (3.6%)	0.49
Exacerbation of pancreatitis	2	1	1
Cholangitis	1	1	0
Cholecystitis	1	1	0
Intraprocedure bleeding	2 (1.1%)	2 (1.3%)	0 (0.0%)	0.72
Evolution of laboratory data after EPBD
Amylase: increase/decrease	17 (9%)/166 (91%)	15 (10%)/140 (90%)	2 (7%)/26 (93%)	0.67
Total bilirubin: increase/decrease	31 (17%)/152 (83%)	28 (18%)/127 (82%)	3 (11%)/25 (89%)	0.34
Time to resume oral intake after EPBD (days)	1.4 ± 0.9	1.4 ± 0.9	1.5 ± 0.9	0.87
Total hospital day (days)	9.2 ± 4.5	9.1 ± 4.5	9.6 ± 4.3	0.63

EPBD, endoscopic papillary balloon dilation; ERCP, endoscopic retrograde cholangiopancreatography; CBD, common bile duct.